Under construction – not a live service
Sign in
Taking people in FranceNo phase

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

Key facts

Who runs it
AbbVie
Where
Besançon, Bordeaux, Calais, Chambray-lès-Tours, Cherbourg, Dijon, La Roche-sur-Yon, La Tronche, Limoges, Lorient, Metz, Montivilliers, Nice, Paris, Rennes, Saint-Denis, Saint-Mandé, Toulon, Toulouse, Trévenans, and Villeurbanne, FranceSee the 22 sitesAlso in 17 other countries, 94 sites
Trial code
Status
Recruiting
People taking part
2,795 people, planned
Started
2 Sept 2025
Expected to end
Aug 2027
Type of study
Observational, 3 groups
Record updated
13 February 2026

Who can take part

Age
12 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
  • Participants Ability to understand study questionnaires, with caregiver support as required for adolescents

Who cannot take part

  • Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
  • Unable or unwilling to comply with study requirements and PRO collection

Where in France

Also in 17 other countries, 94 sites

  • Centre Hospitalier Regional Universitaire de Besancon - Hopital Jean Minjoz /ID# 277459Besançon, FranceContact: Beth RycroftTaking people
  • Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-Andre /ID# 277322Bordeaux, FranceContact: Beth RycroftTaking people
  • Centre Hospitalier de Calais /ID# 277320Calais, FranceContact: Beth RycroftTaking people
  • Centre Hospitalier Régional Universitaire De Tours - Hôpital Trousseau /ID# 277545Chambray-lès-Tours, FranceContact: Beth RycroftTaking people
  • Centre Hospitalier Public du Cotentin - Hôpital Pasteur /ID# 279613Cherbourg, FranceContact: Beth RycroftTaking people
  • Chu Dijon /Id# 277493Dijon, FranceContact: Beth RycroftTaking people
  • Centre Hospitalier Departemental Vendee (Chd Vendee) /ID# 277317La Roche-sur-Yon, FranceContact: Beth RycroftTaking people
  • CHU Grenoble - Hopital Michallon /ID# 277501La Tronche, FranceContact: Beth RycroftTaking people
  • CHU Limoges - Dupuytren 2 /ID# 277323Limoges, FranceContact: Beth RycroftTaking people
  • Centre Hospitalier de Bretagne Sud /ID# 277559Lorient, FranceContact: Beth RycroftTaking people
  • Centre Hospitalier Régional Metz Thionville - Hôpital de Mercy /ID# 277792Metz, FranceContact: Beth RycroftTaking people
  • Groupe Hospitalier Du Havre - Hôpital Jacques Monod /ID# 277506Montivilliers, FranceContact: Beth RycroftTaking people
  • Cideazur /ID# 277316Nice, FranceContact: Beth RycroftTaking people
  • Centre De Santé Sabouraud /ID# 278409Paris, FranceContact: Beth RycroftTaking people
  • Groupe Hospitalier Paris Saint-Joseph /ID# 278270Paris, FranceContact: Beth RycroftTaking people
  • CHU Rennes - Hôpital PONTCHAILLOU /ID# 277527Rennes, FranceContact: Beth RycroftTaking people
  • CHU de la reunion /ID# 277318Saint-Denis, FranceContact: Beth RycroftTaking people
  • Hôpital d'Instruction des Armées Bégin /ID# 278135Saint-Mandé, FranceContact: Beth RycroftTaking people
  • Hôpital d'Instruction des Armées Sainte-Anne /ID# 277458Toulon, FranceContact: Beth RycroftTaking people
  • CHU Toulouse - Hopital Larrey /ID# 277321Toulouse, FranceContact: Beth RycroftTaking people
  • Hopital Nord Franche-Comté /ID# 277560Trévenans, FranceContact: Beth RycroftTaking people
  • Médipôle Lyon-Villeurbanne /ID# 277526Villeurbanne, FranceContact: Beth RycroftTaking people

About the trial

What the trial wants to find out

This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.

The 3 groups in the trial

  • Participants with Vitiligo

    Participants with vitiligo will undergo a single-visit data collection per routine clinical practice

  • Participants with Alopecia Areata

    Participants with alopecia areata will undergo a single-visit data collection per routine clinical practice

  • Participants with Hidradenitis Suppurativa

    Participants with hidradenitis suppurativa will undergo a single-visit data collection per routine clinical practice

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)
Record updated
13 February 2026